MelanomaImmunotherapySkin NeoplasmsMART-1 AntigenImmunotherapy, AdoptiveAntigens, NeoplasmMelanoma, Experimentalgp100 Melanoma AntigenCancer VaccinesMonophenol MonooxygenaseImmunotherapy, ActiveUveal NeoplasmsDesensitization, ImmunologicHLA-A2 AntigenNeoplasm ProteinsMelanoma-Specific AntigensLymphocytes, Tumor-InfiltratingNeoplasm MetastasisProto-Oncogene Proteins B-rafT-Lymphocytes, CytotoxicCell Line, TumorCD8-Positive T-LymphocytesSentinel Lymph Node BiopsyNeoplasm StagingDendritic CellsNevus, PigmentedInterleukin-2Antibodies, NeoplasmTreatment OutcomeDysplastic Nevus SyndromeAntibodies, MonoclonalTumor Cells, CulturedT-LymphocytesEpitopes, T-LymphocyteCytotoxicity, ImmunologicMelanoma, AmelanoticPrognosisVitiligoChoroid NeoplasmsHLA-A AntigensDacarbazineLymphatic MetastasisCysteinyldopaEye NeoplasmsAntineoplastic AgentsNeoplasmsTumor Markers, BiologicalLymphocyte ActivationSurvival AnalysisG(M2) GangliosideS100 Calcium Binding Protein beta SubunitLymph NodesAdministration, SublingualInterferon-alphaNeoplastic Cells, CirculatingHLA-A1 AntigenVaccines, SubunitFlow CytometryDisease-Free SurvivalSublingual ImmunotherapyLymph Node ExcisionCanarypox virusHemocyaninAdjuvants, ImmunologicCombined Modality TherapyInterferon-gammaCD4-Positive T-LymphocytesReverse Transcriptase Polymerase Chain ReactionBCG VaccineRhinitis, Allergic, SeasonalAntineoplastic Combined Chemotherapy ProtocolsMelaninsDrug Administration ScheduleSelf-ExaminationSurvival RateMonitoring, ImmunologicMice, Inbred C57BLDisease ProgressionImmunohistochemistryTime FactorsEpitopesS100 ProteinsMembrane GlycoproteinsGene Expression Regulation, NeoplasticClone CellsAntigen PresentationEnzyme-Linked Immunosorbent AssayReceptor, Melanocortin, Type 1Clinical Trials as TopicPeptide FragmentsAllergensRecombinant ProteinsNeoplasm TransplantationInjections, SubcutaneousAntigens, CDCTLA-4 AntigenLymphoscintigraphyKiller Cells, NaturalVaccinesNeoplasm Recurrence, Local